Strength of the evidence: Adjuvant therapy for resected pancreatic cancer

Vincent J. Picozzi, Peter W.T. Pisters, Selwyn M. Vickers, Steven M. Strasberg

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Pancreatic cancer remains one of the greatest challenges within oncology. Among resected patients, 5-year survival is typically only 10-25%. Among eight major randomized trials for resected pancreas cancer, five (GITSG, EORTC, ESPAC-1, RTOG 9704, and CONKO-1), containing a total of over 1,200 patients, have shaped world opinion on this subject. These trials have many significant methodological differences. Major conclusions that can be drawn from these trials in composite are (1) adjuvant chemotherapy is superior to observation following pancreaticoduodenectomy for pancreatic cancer, (2) gemcitabine is superior to 5-FU as adjuvant chemotherapy, and (3) the benefit of adjuvant chemoradiation is uncertain. Additional randomized trials are needed to address significant areas of controversy within available data.

Original languageEnglish
Pages (from-to)657-661
Number of pages5
JournalJournal of Gastrointestinal Surgery
Issue number4
StatePublished - Apr 1 2008


  • Adjuvant therapy
  • Pancreatic cancer
  • Pancreatic neoplasms
  • Postgraduate course


Dive into the research topics of 'Strength of the evidence: Adjuvant therapy for resected pancreatic cancer'. Together they form a unique fingerprint.

Cite this